Stock Scorecard



Stock Summary for uniQure N.V. (QURE) - $14.76 as of 3/19/2026 6:53:34 PM EST

Total Score

9 out of 30

Safety Score

34 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for QURE

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for QURE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for QURE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for QURE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for QURE (34 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for QURE

Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline – Company Announcement - FT.com 3/19/2026 9:39:00 PM
uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Ac 3/19/2026 8:10:00 PM
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm 3/19/2026 7:10:00 PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE 3/19/2026 2:10:00 PM
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard 3/19/2026 12:10:00 PM
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors Have Opportunity to Lead Class Action Lawsuit! 3/18/2026 5:40:00 PM
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data 3/18/2026 4:40:00 PM
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data 3/18/2026 4:39:00 PM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE 3/18/2026 12:39:00 PM
QURE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in uniQure N.V. Securities Lawsuit -- The Gross Law Firm 3/18/2026 6:38:00 AM

Financial Details for QURE

Company Overview

Ticker QURE
Company Name uniQure N.V.
Country USA
Description uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 14.76
Price 4 Years Ago 22.67
Last Day Price Updated 3/19/2026 6:53:34 PM EST
Last Day Volume 1,944,205
Average Daily Volume 4,652,427
52-Week High 71.50
52-Week Low 7.76
Last Price to 52 Week Low 90.21%

Valuation Measures

Trailing PE N/A
Industry PE 20.29
Sector PE 64.33
5-Year Average PE -3.48
Free Cash Flow Ratio 11.44
Industry Free Cash Flow Ratio 10.66
Sector Free Cash Flow Ratio 28.29
Current Ratio Most Recent Quarter 10.43
Total Cash Per Share 1.29
Book Value Per Share Most Recent Quarter 3.19
Price to Book Ratio 5.01
Industry Price to Book Ratio 79.77
Sector Price to Book Ratio 37.47
Price to Sales Ratio Twelve Trailing Months 60.67
Industry Price to Sales Ratio Twelve Trailing Months 12.89
Sector Price to Sales Ratio Twelve Trailing Months 5.26
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 62,529,000
Market Capitalization 922,928,040
Institutional Ownership 100.89%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -18.20%
Annual Earnings Growth 16.94%
Reported EPS 12 Trailing Months -3.46
Reported EPS Past Year -3.27
Reported EPS Prior Year -4.87
Net Income Twelve Trailing Months -198,971,000
Net Income Past Year -198,971,000
Net Income Prior Year -239,556,000
Quarterly Revenue Growth YOY 6.60%
5-Year Revenue Growth -15.57%
Operating Margin Twelve Trailing Months -901.00%

Balance Sheet

Total Cash Most Recent Quarter 80,240,000
Total Cash Past Year 80,240,000
Total Cash Prior Year 158,930,000
Net Cash Position Most Recent Quarter 30,541,000
Net Cash Position Past Year 30,541,000
Long Term Debt Past Year 49,699,000
Long Term Debt Prior Year 51,324,000
Total Debt Most Recent Quarter 49,699,000
Equity to Debt Ratio Past Year 0.80
Equity to Debt Ratio Most Recent Quarter 0.80
Total Stockholder Equity Past Year 198,901,000
Total Stockholder Equity Prior Year -6,752,000
Total Stockholder Equity Most Recent Quarter 198,901,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -178,735,000
Free Cash Flow Per Share Twelve Trailing Months -2.86
Free Cash Flow Past Year -178,402,000
Free Cash Flow Prior Year -186,096,000

Options

Put/Call Ratio 0.06
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.84
MACD Signal -2.22
20-Day Bollinger Lower Band 13.81
20-Day Bollinger Middle Band 22.65
20-Day Bollinger Upper Band 31.48
Beta 0.77
RSI 43.03
50-Day SMA 22.14
150-Day SMA 13.28
200-Day SMA 15.05

System

Modified 3/19/2026 6:27:39 AM EST